Picture loading failed.

Anti-TACSTD2 therapeutic antibody (Pre-made Sacituzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-503-1mg 1mg Inquiry
GMP-Bios-ab-503-10mg 10mg Inquiry
GMP-Bios-ab-503-100mg 100mg Inquiry
GMP-Bios-ab-503-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TACSTD2 therapeutic antibody (Pre-made Sacituzumab biosimilar,Whole mAb ADC)
INN Name Sacituzumab
TargetTACSTD2
FormatWhole mAb ADC
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesIBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University
Conditions ApprovedBreast cancer
Conditions ActiveProstate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma
Conditions Discontinuedna
Development Techna